Mycapssa® (octreotide) – New orphan drug approval
June 26, 2020 - Chiasma announced the FDA approval of Mycapssa (octreotide), for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
Download PDF
